Lonza divests capsules and health ingredients business to Lone Star Funds for CHF 2.3 billion, finalizing its shift to a pure-play CDMO model by H2 2026.
chemweek · 2026-03-09 20:41
Lonza's 2025 full-year earnings increased on strong CDMO momentum but missed estimates, with further sales and margin growth expected in 2026.
chemweek · 2026-01-28 18:13
Lonza confirmed its 2025 outlook following strong Q3 performance, though it anticipates a 2.5%-3.5% negative impact on sales and earnings due to a weakening US dollar. Margins are expected to remain m
chemweek · 2025-10-23 17:12
ChemBrief